Usually the best stocks to buy have not already tripled in value within the past six months.
But then there's Intercept Pharmaceuticals Inc. (Nasdaq:
ICPT).
Price: 274.20 | Ch: -4.44 (-1.6%)
This biotech has attracted a lot of attention this year because of
its innovative and promising drug, obeticholic acid (OCA). In trials,
OCA has proven effective in treating patients suffering from a liver
disease known as nonalcoholic steatohepatitis (NASH). This chronic
liver disease can cause inflammation and scarring, which may lead to
cirrhosis, liver failure, and death.
In fact, it was the Jan. 9 news that a National Institutes of Health
(NIH) study was stopped early because it had found that OCA satisfied
its requirements in improving the condition of the 283 test patients
that propelled ICPT stock up more than 280% in one day.
(more)
Please share this article
No comments:
Post a Comment